Estrogen receptor (ER)-negative breast cancer cells display extensive methylation of the ER gene CpG island and elevated DNA methyltransferase (DMT) expression compared to ER-positive cells. The present study demonstrates that DMT protein levels tightly correlate with S phase fraction in ER-positive cells, whereas ER-negative cells express DMT throughout the cell cycle. In addition, levels of p21
Introduction
One major challenge in improving the treatment of breast cancer is understanding and overcoming resistance to endocrine therapy. Approximately onethird of human breast cancers lack estrogen receptor a (ER). These ER-negative tumors rarely respond to hormonal therapy with agents like the antiestrogen tamoxifen and are associated with shorter disease-free survival (McGuire, 1978; Samaan et al., 1981; Early Breast Cancer Trialists Collaborative Group, 1998) . Therefore, de®ning how and why tumors become ERnegative is a critical step for improving breast cancer therapeutic outcome. The molecular mechanisms underlying lack of estrogen receptor expression are poorly understood, but it has been hypothesized that ER-negative breast cancer cells may be derived from ER-positive cells that have acquired the ability to grow independently of estrogen and have lost expression of the gene.
Recent ®ndings suggest that abnormal methylation of the ER gene CpG island may be important for silencing ER gene expression as some breast cancers progress to an aggressive, hormone insensitive phenotype (Ottaviano et al., 1994; Lapidus et al., 1996 Lapidus et al., , 1998b Ferguson et al., 1995) . CpG islands are cytosine ± guanosine rich areas located in the 5' regulatory region of some genes (Bird, 1986) . Methylation of a CpG island results in transcriptional silencing of the associated gene, via a change in chromatin con®rmation that inhibits transcription (Kass et al., 1997) . Cancer cells often display anomalous patterns of DNA methylation, with site speci®c hypermethylation in CpG island and hypomethylation of bulk genomic DNA (reviewed in Laird and Jaenisch, 1996; Counts and Goodman, 1995) .
The CpG island in the promoter region of the ER gene is extensively methylated in established ERnegative breast cancer cell lines and primary tumors, but remains unmethylated in normal tissues and ERpositive breast cancer cell lines. Furthermore, treatment of the ER-negative cell line MDA-MB-231 with an inhibitor of DNA methylation results in demethylation of the ER CpG island and restores expression of a functional estrogen receptor (Ferguson et al., 1995) . However, it is not clear whether CpG island methylation initiates or maintains ER gene silencing, or whether aberrant methylation intrinsically accompanies the transition to an estrogen independent, ERnegative phenotype.
It is possible that abnormal methylation patterns result from overexpression of the enzyme that catalyzes cytosine methylation, DNA (cytosine-5) methyl-transferase (DMT). Expression of DMT is required for normal maintenance methylation, but changes in enzyme expression or activity may also promote de novo changes in a cell's methylation patterns. Increased expression of DMT is an early event in two experimental models of cancer (Belinsky et al., 1996; Miyoshi et al., 1993) , and overexpression of DMT can promote a transformed phenotype in NIH3T3 cells (Wu et al., 1993) . In ER-negative breast cancer cell lines, DMT RNA and protein levels are signi®cantly elevated compared to ER-positve cell lines (Ottaviano et al., 1994; Ferguson et al., 1997) , but little is known about the regulation of DMT expression and activity in breast cancer. If deregula-tion of DMT is necessary to initiate or maintain aberrant methylation of the ER CpG island, then examining the regulation of DMT expression in breast cancer may greatly improve our understanding of breast cancer progression.
We therefore studied the expression of DMT in three panels of established human breast cancer cell lines that potentially represent dierent stages of breast cancer progression (estrogen-dependent ER-positive cell lines, estrogen-independent ER-positive lines, and ER-negative lines). We found that DMT expression was tightly correlated with S phase fraction in ERpositive cells, while ER-negative cells expressed DMT throughout the cell cycle. Thus, breast cancer cells may acquire characteristics that allow them to escape normal cell cycle-dependent regulatory controls on DMT expression during the process of tumor progression. Activation of peptide growth factor signaling pathways, which is common in breast cancers, led to increased DMT expression in ERpositive MCF7 cells without a concomitant change in S phase fraction. However, acquisition of an estrogen independent phenotype in MCF7 cells, even in conjunction with elevated DMT expression, was not inherently accompanied by aberrant methylation of the ER gene. Together, these data imply that multiple steps are required for de novo methylation of the ER CpG island.
Results

DMT levels correlate with S phase fraction in ER-positive, but not ER-negative cells
It had been previously demonstrated with six breast cancer cell lines that DMT mRNA, protein, and enzyme activity (Ottaviano et al., 1994; Ferguson et al., 1997) , were elevated in ER-negative breast cancer cells compared to ER-positive cells. Because DMT protein is known to be expressed primarily during the S phase of the cell cycle in normal cells (Szyf et al., 1985 (Szyf et al., , 1991 , we ®rst determined whether the elevated DMT protein level in ER-negative cell lines was simply due to a large S phase fraction in those cells. Cell cycle distribution and DMT expression were examined during exponential growth in a larger panel of ten breast cancer cell lines (4 ER-positive and 6 ERnegative). For each cell line, nuclei for FACS analysis and total protein lysates for Western analysis were prepared concurrently. The results of the FACS analysis are shown in Figure 1 . ER-positive cell lines generally had a higher G 1 fraction and a lower S phase fraction than the ER-negative lines. Western analysis con®rmed that DMT protein levels were also lower in ER-positive than ER-negative cells (Figure 1 ). However, statistical analysis of these results showed a signi®cant correlation between S phase fraction and DMT protein level in ER-positive cells (r=0.99, P=0.009, Figure 2a ), but not ER-negative cells (r=0.06, P=0.91, Figure 2b ), indicating that elevated DMT levels in ER-negative cells could not be explained solely by a change in S phase fraction. There was no signi®cant correlation between DMT level and the fraction of cells in the other phases of the cell cycle (G 1 or G 2 /M).
DMT and p21 are inversely correlated in breast cancer cells
A recent study reported that DMT can bind to PCNA (proliferating cell nuclear antigen), and that p21 CIP1 can disrupt the association between DMT and PCNA, possibly aecting the activity of these proteins (Chuang et al., 1997) . We therefore examined the levels of PCNA and p21 in the panel of ER-positive andnegative breast cancer cells (Figure 1 ). As shown in Figure 2c , DMT protein levels were inversely correlated with the level of p21 in breast cancer cells (r=0.69, P=0.03). Most ER negative cells expressed little or no p21, while expression levels were quite high in most ER-positive cell lines. PCNA expression did not vary greataly among the cell lines, and was not signi®cantly correlated with DMT expression ( Figure  1 ).
DMT antisense transfection leads to altered DMT/p21 ratio
The relative ratio of DMT protein to p21 protein was altered in MDA-231 cells stably transfected with a DMT antisense expression construct (Figure 3 ). Clones with decreased DMT expression also tended to have elevated p21 protein levels (mean relative DMT/p21 ratio of 1.7 compared to parental MDA-231 cells or vector-transfected controls (mean relative ratio of 42).
ER-negative cells express DMT protein in all phases of the cell cycle
To determine the cell cycle distribution of DMTexpressing cells, nuclei from exponentially growing cells were harvested, ®xed, and analysed concurrently for PI staining and DMT expression. As shown in Figure 4 and Table 1 , there was a striking dierence between ER-positive and ER-negative cells. About 90% of cells in ER-negative lines expressed detectable amounts of DMT protein, whereas only 40% or less of ER-positive cells contained a 
Estrogen independence does not lead to methylation of the ER CpG island in MCF7 cells
Many ER-negative breast tumors have up-regulated growth factor signaling pathways. To determine whether such pathways might play a role in the overexpression of DMT in breast cancer, MCF7 cells were treated with transforming growth factor a. Within 4 h, we observed a twofold increase in DMT protein levels without a concurrent increase in S phase fraction (not shown). Therefore, another panel of cell lines ( Figure 5 ) was examined to determine whether progression of MCF7 cells to estrogen independence was accompanied by increased DMT expression and/or ER gene methylation.
The ER CpG island remained completely unmethylated in all of these transfected and selected MCF7 derivatives ( Figure 6 ). This is in marked contrast to another MCF7 derivative, the MCF7(ADR) line, shown in Figure 3 . The MCF7(ADR) cells developed an ER-negative phenotype with extensive methylation of the ER CpG island (Lapidus et al., 1998b) following selection for adriamycin resistance (Vickers et al., 1988) . . Vector controls were transfected by vector plasmids without insert DNA. DMT was not down-regulated in the ®rst three antisense clones (1 ± 3), and like the vector controls, p21 was barely detectable in these cell lines. In contrast, the three antisense clones (4 ± 6) that did exhibit reduced DMT protein also showed up-regulation of p21 protein Selection for estrogen independence does not lead to deregulation of DMT We next examined DMT protein levels and cell cycle distribution in these lines. Cell lines that had been selected in vivo for estrogen independence (MIII, LCC1, and LCC2) manifested DMT protein levels and S phase fractions similar to those observed for parental MCF7 cells (Figure 7 ). Vector control lines that had been selected for growth in CCS in vitro (MCN4c and HCopoolc) exhibited a comparatively low S phase fraction and expressed a relatively small amount of DMT. More importantly, all MCF7 variant lines selected for growth in the absence of estrogen in vitro or in vivo showed the same correlation between S phase and DMT level that was observed in the original panel of ER-positive cells (Figure 8a , r=0.858, P=0.03). The two regression lines are nearly parallel, with only a small shift to the left for the MCF7 variant lines, perhaps as a result of growth in CCS rather than FCS.
DMT protein level is elevated in transfected MCF7 cell lines
Constitutive expression of FGF1, FGF4, or Raf led to increased DMT protein levels compared to vectortransfected controls (Figures 7 and 8b) . Transfection of MCF7 cells with FGF1 (a18) or FGF4 (MKL4) resulted in a fourfold increase in DMT levels that was not associated with a shift in S phase fraction (Figure 8b ). In contrast, transfection with constitutively active Raf promoted a smaller increase in DMT level in conjunction with a shift in S phase fraction. In Figure 8b , the line showing the relationship between Raf14c and its vector control is parallel to the two regression lines in 8a. were selected for estrogen independence in vitro over a period of about 9 months. (b ) The MIII and LCC1 lines were sequentially selected for estrogen-independent growth in nude mice, and LCC2 was derived from LCC1 by selection for resistance to tamoxifen in vitro Figure 6 The ER CpG island remains unmethylated in estrogen independent lines derived from the ER-positive human breast cancer cell line MCF-7, as shown in Figure 5 . Methylation speci®c PCR was used to assess the methylation status of multiple CpGs within the island. Representative results from one primer set are shown, since four dierent primer sets gave identical results. u=primers speci®c for unmethylated DNA, m=primers speci®c for methylated DNA. Water served as a negative control and DNA from MDA-MB-231 cells served as a positive control for the methylated reaction A trend toward inverse correlation between DMT and p21 levels was noted among the MCF7 derivatives, but it did not achieve statistical signi®cance (Figure 8c) . However, the two FGF-transfected cell lines (a18 and MKL4) with signi®cantly elevated DMT in the absence of increased S phase fraction, also showed a substantial decrease in p21 protein level (about sixfold).
Discussion
De®ning the mechanism by which breast cancer cells develop an ER-negative phenotype is a crucial step for developing novel therapeutic strategies for hormone insensitive breast cancers. Hypermethylation of the ER gene CpG island is the only molecular change that has been consistently identi®ed with the lack of ER gene expression in ER-negative breast tumors to date (Lapidus et al., 1998a,b) . However, it is not known how the ER gene becomes aberrantly methylated in these tumors. In ®broblasts, DMT overexpression can lead to de novo methylation of many promoter sequences (Vertino et al., 1996) . Several studies suggest that DMT expression is commonly elevated in cancer cells compared to normal cells of the same tissue type (Laird and Jaenisch, 1996) , perhaps providing an explanation for the high frequency of abnormal CpG island methylation in cancer cells.
However, a recent study of colon tumors and matched normal colonic mucosa indicated that DMT expression in tumors is only modestly increased above that seen in normal colon tissue, and the increase in DMT expression was correlated with increased histone H4 expression, a measure of S phase-speci®c gene expression (Lee et al., 1996) . Those results were perhaps not surprising in light of the fact that DMT expression and activity are known to vary with the cell cycle (Szyf et al., 1985 (Szyf et al., , 1991 . In vivo, DMT activity of non-proliferating tissues increases following a mitogenic stimulus with a time course coincident with entry into S phase (Szyf et al., 1985) . In vitro, DMT enzyme activity and mRNA levels in ®broblasts are both maximal during the S phase portion of the cell cycle (Szyf et al., 1991) .
Because DMT levels are elevated in ER-negative human breast cancer cell lines compared to ER-positive lines, it was important to determine whether this dierence was due simply to altered cell cycle distributions or to a more complex phenomenon. In ER-positive cells, DMT expression was tightly correlated with S phase fraction. However, elevated DMT levels in ER-negative cells could not be explained solely by a change in cell cycle progression because DMT levels were not correlated with S phase in these cell lines. Thus, breast cancer cells may acquire characteristics that allow them to escape normal cell cycle-dependent regulatory controls on DMT expression during the process of tumor progression.
An increase in DMT expression in the absence of a concurrent increase in the percentage of cells in S phase could be achieved in one of two ways. First, DMT protein could simply be expressed at abnormally high levels during S phase. Alternatively, cell cycle dependent regulation of DMT protein expression could be lost or altered, resulting in inappropriate expression of the protein in other phases of the cell cycle. Our results indicate that the latter occurs in breast cancer. We demonstrated a striking dierence between ER-positive and ER-negative cell lines in the cell cycle distribution of cells expressing detectable levels of DMT protein. DMT was detectable by FACS analysis during all phases of the cell cycle in ERnegative lines, with nearly all of the cells staining positive for DMT. In contrast, only 40% or less of ERpositive cells expressed detectable amounts of DMT, with the majority of G 1 phase cells negative for DMT, and the majority of S phase cells positive for DMT.
The normal association of DMT with the S phase of the cell cycle is not surprising, given the recent studies which reported that DNA methylation takes place concurrently with replication, perhaps via DMT binding to PCNA at the replication fork (Chuang et al., 1997; Araujo et al., 1998) . The cell cycle inhibitor p21 CIP1 can disrupt the association between DMT and PCNA, perhaps aecting the activity of the two proteins (Chuang et al., 1997) . Furthermore, levels of DMT and p21 proteins were inversely related in normal and SV-40 transformed human ®broblasts. We therefore examined the levels of PCNA and p21 in the panel of ER-positive and -negative breast cancer cells and found that DMT protein levels were inversely correlated with the level of p21 in breast cancer cells. In contrast, PCNA expression did not vary greatly among the cell lines, and was not signi®cantly correlated with DMT expression. It has been suggested (Chuang et al., 1997) that the transforming eect of DMT overexpression observed by others (Wu et al., 1993) may be due in part to the ability of DMT to compete with p21 for PCNA binding, thereby promoting the G 1 -S phase transition. By binding to PCNA in place of p21, excess DMT could increase the level of active cyclin-dependent kinases, promoting Rb phosphorylation and thus progression through the cell cycle. If that hypothesis is correct, then the relatively high S phase fraction of ER-negative cells may be related to the high ratio of DMT to p21 in these cells. In this scenario, the increased DMT level in ERnegative cells could be a cause, rather than an eect, of a higher S phase fraction in those cells. However, the question still remains as to how DMT expression is deregulated in ER-negative breast cancer cells.
One potential mechanism for upregulation of DMT is altered transcriptional regulation. The mouse DMT gene has been reported to contain AP1 sites that can regulate its expression Macleod et al., 1995) . More recently, it was demonstrated that transformation of human ®broblasts by fos, a component of AP1, is dependent upon a fos-induced increase in DMT expression and activity (Bakin and Curran, 1999) . Because many ER-negative tumors overexpress growth factor receptors whose signaling pathways include AP1 activation (Dickson and Lippman, 1995) , we hypothesized that these pathways may play a role in the upregulation of DMT expression. In fact, the ER-negative breast cancer cell line with the highest level of DMT expression (MDA-MB-468) is known to overexpress the epidermal growth factor receptor (Filmus et al., 1985) . Peptide growth factors stimulate several intracellular signaling pathways, but it is the Ras kinase pathway that leads directly to activation of the transcription factor AP1. Interestingly, the Hs578t cell line, which expressed DMT at a much higher level than would have been predicted by its relatively low S phase fraction, has a constitutively active mutant form of Ras (Kraus et al., 1984) .
A second panel of cell lines, all of which were derived from the ER-positive MCF-7 line, was examined to further address these questions. Statistical analysis showed that DMT expression was still correlated with S phase in the MCF7-derived cell lines that had been selected for growth in the absence of estrogen, suggesting that aberrant expression of DMT does not necessarily accompany the progression to estrogen independence. However, constitutive overexpression of FGF1 or 4 led to a signi®cant upregulation of DMT expression that could not be accounted for by a shift in S phase fraction. These results demonstrate that activation of growth factor signaling pathways can have an impact on the regulation of DMT expression. Overexpression of a constitutively active Raf kinase also led to increased DMT expression, but in this case, the change in expression was fully explained by a corresponding increase in S phase fraction. It is unclear why the results were dierent for the FGF and Raf transfectants, since all three proteins activate a Map kinase cascade. However, growth factors activate multiple intracellular pathways in addition to the Map kinase pathway. Perhaps activation of multiple pathways is necessary to disrupt the regulation of DMT protein expression in these cells. It is important to note that DMT protein levels can be regulated at the posttranscriptional level (Szyf et al., 1991) , so even if DMT transcription is upregulated via Raf or AP1 activation, this may not be sucient to elevate DMT protein levels. Additional post-transcriptional or post-translational regulatory mechanisms may supersede an increase in transcriptional activity.
The elevated DMT protein expression in FGF transfectants was accompanied by a signi®cant decrease in p21, again suggesting a reciprocal relationship between these two proteins. Interestingly, we have also observed that the DMT/p21 ratio is signi®cantly decreased in MDA-231 cells that are stably transfected with a DMT antisense expression vector. The fact that we have observed a similar phenomenon in two very dierent transfected model systems raises the question as to whether association with PCNA might aect the stability of these proteins. For example, because DMT and p21 compete for the same binding site on PCNA, an increase in DMT expression might promote dissociation of p21 from PCNA, perhaps making p21 more susceptible to ubiquitination and proteosome degradation (Maki and Howley, 1997) . A decrease in DMT expression would then be expected to have the opposite eect on p21 stability.
In spite of our previous ®ndings showing a connection between DMT expression and loss of ER expression, the elevated DMT expression in these ERpositive, estrogen independent cells was not sucient to promote ER gene methylation and loss of ER gene expression. All cell lines derived from MCF-7 cells via transfection or selection grow in an estrogen-independent manner (Clarke et al., 1994; El-Ashry et al., 1997; Kern et al., 1994) . However, all but one (Raf14c) continue to express ER protein. Furthermore, the ER CpG island remained completely unmethylated in all of these cell lines, including Raf14c. Thus, acquisition of an estrogen-independent phenotype, even in conjunction with loss of ER expression in the Raf14c line, was not sucient to promote ER gene silencing via CpG island methylation. These results are not due to an inherent inability of the MCF7 cells to methylate the ER gene. We know that MCF7 cells can acquire the capability to methylate the ER gene and silence its transcription because the MCF7ADR line, which was selected for resistance to adriamycin, is ER negative and shows deregulated DMT expression and extensive ER CpG island methylation (Lapidus et al., 1998b) .
These results suggest that ER gene transcription must ®rst be down-regulated by another mechanism, perhaps via altered availability of a critical transcription factor, prior to DNA methylation. In this scenario, aberrant CpG island methylation may act to consolidate and strengthen transcriptional silencing of the associated gene. Although it has not been de®nitively demonstrated that ER-positive cells progress to ER-negative breast tumors, we propose that such a transition would require the tumor cells to pass through at least three stages during the progression from an estrogen dependent phenotype, to a stable, ER-negative phenotype. These stages would include acquisition of estrogen independence, loss of ER transcription, and ®nally ER CpG island methylation. It is not yet clear whether aberrant DMT expression precedes ER gene methylation, but our results with the Raf-transfected cell line suggest that loss of ER expression alone is not sucient to trigger ER gene methylation. Although elevated DMT protein expression in the FGF model system was not sucient to induce ER CpG island methylation, deregulation of DMT expression or activity may still be a prerequisite for de novo methylation of the ER gene in breast cancer cells. Alternatively, an increase in DMT expression may be necessary to maintain the abnormal methylation pattern after the gene has been silenced.
Materials and methods
Cell lines
Four ER-positive (MCF-7/WT, ZR-75-1, T47D, and MDA-MB-134) and six ER negative (MCF-7/Adr, Hs578t, MDA-MB-231, MDA-MB-435, MDA-MR-453, and MDA-MB-468) human breast cancer cell lines were acquired and routinely maintained as previously described (Ottaviano et al., 1994) . Eight additional cell lines derived from the ERpositive MCF-7 line were also examined ( Figure 5 ). Raf14c (overexpressing a constitutively active form of Raf) and its vector control, HCopoolc, as well as MKL4 and a18 cells (which overexpress FGF4 and FGF1 respectively) and their vector control, MCN4 were provided by Dr Dorraya ElAshry and Dr Francis Kern of the Lombardi Cancer Center and Southern Research Institute, respectively (El-Ashry et al., 1997; Kern et al., 1994) . These transfected lines have acquired estrogen independent growth as a result of their speci®c gene overexpression and are grown continuously in the absence of estrogen. The MCN4 and HCopoolc cell lines were selected in vitro for estrogen independent growth over a period of about nine months (El-Ashry et al., 1997; Kern et al., 1994) . MCF-7/MIII, MCF-7/LCCI, and MCF-7/LCC2 (Clarke et al., 1994) were a gift from Dr Robert Clarke (Lombardi Cancer Center, Washington DC, USA). The MIII and LCC1 lines sequentially selected for estrogen-independent growth in nude mice, and LCC2 was derived from LCC1 by selection for resistance to tamoxifen in vitro. All estrogen independent MCF7 derivatives were grown in IMEM without phenol red supplemented with 10% serum that had been charcoalstripped to remove all steroid hormones (CCS, HyClone Laboratories, Logan, Utah, USA). With the exception of Raf14c, all MCF7 derivatives continue to express ER protein.
FACS analysis
Cells were plated in 100-mm tissue culture dishes concurrently for cell cycle analysis by FACS and for Western analysis. Two days later, exponentially growing cells were harvested at about 70% con¯uence. Nuclei were isolated and stained with propidium ioidide (PI) for cell cycle analysis according to the method of Vindelov et al. (1983) .
To determine the cell cycle distribution of cells expressing DMT, nuclei were ®xed and stained by immuno¯uorescence for DMT along with PI. Growing cells were harvested by trypsinization and then swelled in HSSE buer (20 mM HEPES, pH 7.0, 0.75 mM spermidine, 0.15 mM spermine, 0.1 mM EDTA, 1 mM DTT, 1 mM phenylmethylsulfonyl uoride) on ice for 20 min. Cells were lysed in a dounce homogenizer and nuclei were pelleted by centrifugation. The nuclei were resuspended in 0.5 M sucrose/HSSE, layered on a cushion of 1.5 M sucrose/HSSE, and centrifuged for 20 min at 13 000 g. Isolated nuclei were then ®xed with 3% paraformaldehyde in phosphate buered saline (PBS) for 10 min on ice, washed with PBS, and stored at 7708 C prior to FACS analysis.
The nuclei were resuspended in permeabilization buer (PBS with 4% goat serum and 0.1% Triton X-100), washed with PBS, and incubated with 1 mg/ml primary DMT antibody in PBS with 1% BSA for 2 h at room temperature (RT). Following washes in PBS/1% BSA, the nuclei were incubated for 1 h at RT with an FITC-conjugated anti-rabbit secondary antibody (Sigma) diluted 1/500 in PBS/1% BSA. Nuclei were washed again in PBS and then stained with PI as above. FACS analysis was repeated at least three times for all cell lines examined.
Preparation and characterization of anti-DMT antiserum
With the help of Research Genetics, Inc., rabbit polyclonal antiserum was raised against a peptide derived from the Nterminal region of DMT (NH 3 -MADANSPPKPLSKPRT-PRRSCOOH). The peptide was conjugated to KLH and used for rabbit immunization and boosting. The resultant antiserum against the peptide recognized a single polypeptide at the expected molecular weight on an immunoblot of proteins derived from a variety of human cell lines, and depleted DNA methyltransferase activity from nuclear extracts (not shown). Anity puri®ed antibody was used for FACS and Western analysis.
Western analysis
Cells were plated as described above. Two days later, total cell lysates were prepared. Cells were washed with cold PBS and then scraped into cold lysis buer (50 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10 mg/ml PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin). After a 10 min incubation on ice, lysates were spun for 10 min in a cold microcentrifuge to remove cellular debris and were frozen at 7708C. Proteins were boiled and separated by SDS ± PAGE and then transferred to nitrocellulose membranes. For DMT analysis, 75 mg of protein from each sample were separated on 6.5% polyacrylamide gels. For PCNA and p21, 25 mg of protein were run on 14% gels. Blots were blocked in 7% BSA in Tris-buered saline with Tween-20 (TBST; 10 mM Tris, pH 7.4, 150 mM NaCl, 1% Tween-20) for 1 h at room temperature and then incubated in TBST with 1% BSA and the following antibodies (1 mg/ml): DMT (polyclonal), PCNA (monoclonal, Oncogene), or p21 (monoclonal, Oncogene). Proteins were visualized with an HRP-linked second antibody (1/5000 in TBST with 1% BSA) and a chemiluminescent detection system (Pierce, Rockford, IL, USA). India ink staining of the membranes demonstrated equal loading and transfer of the samples.
Densitometry and statistical analysis
Western band intensities were quantitated with IPLab Gel 1.5 (Scanalytics, Fairfax, VA, Canada). Relative protein levels were calculated relative to the values obtained for the parental MCF-7 line that was assigned an arbitrary value of 1. Correlations between relative DMT protein levels and the other variables examined (% cells in S, G 1 , or G 2 /M phase, and relative p21 or PCNA protein levels) were calculated with Statview 4.02. Signi®cance was set at P50.05.
DMT antisense transfection
MDA-231 cells were stably transfected with pCMV-TMH, a human antisense DMT constitutive expression plasmid provided by Dr Paula Vertino at the Emory University School of Medicine (Vertino et al., 1996) . Clones were selected in 1 mM G418 and screened for altered DMT expression by Western analysis.
Methylation speci®c PCR (MSP)
ER CpG island MSP was performed as previously described (Lapidus et al., 1998b) . Four primer sets that span the ER CpG island were used for the analysis (primers sets 1, 3, 4 and 5 from Lapidus et al., 1998b) . Controls lacking DNA were included with each set of PCR reactions. Ten ml of total reaction was run on a 3% TBE/agarose gel, stained with ethidium bromide, and visualized by UV light. Eagle Eye technology (Stratagene) and standard graphic software packages were utilized to prepare ®gures.
